Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis
Selected in The Lancet by R. Dworakowski
Sammy Elmariah, Laura Mauri, Gheorghe Doros, Benjamin Z Galper, Kelly E O'Neill, Prof Philippe Gabriel Steg, Prof Dean J Kereiakes, Dr Robert W Yeh
Lancet, 385(9970), 792–798
LinkRead the article
Latest contributionsVon Willebrand Factor Multimers during Transcatheter Aortic-Valve Replacement Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis Incidence of infective endocarditis in England, 2000–13: a secular trend, interrupted time-series analysis
What is known
In patients at high risk of ischaemic events, dual antiplatelet therapy might prevent potentially fatal thrombotic events but data are conflicting. A recently published DAPT Study suggests that extended use of dual antiplatelet therapy reduces death, myocardial infarction, and stroke at 30 months for the price of increased all-cause mortality.
- 14 eligible trials that randomly assigned 69 644 participants to different durations of dual antiplatelet therapy
- compared with aspirin alone or short duration dual antiplatelet therapy (≤6 months), continued treatment was not associated with a difference in all-cause mortality (hazard ratio [HR] 1.05, 95% credible interval [CrI] 0.96–1.19; p=0.33)
- cardiovascular (1.01, 0.93–1.12; p=0.81) and non-cardiovascular mortality (1.04, 0.90–1.26; p=0.66) were no different with extended duration versus short duration dual antiplatelet therapy or aspirin alone.
- extended duration dual antiplatelet therapy was not associated with a difference in the risk of all-cause, cardiovascular, or non-cardiovascular death compared with aspirin alone or short duration dual antiplatelet therapy.
This study provides some reassurance about extended use of dual antiplatelet therapy but does not support it as well. However dual antiplatelet therapy can reduce the risk of thromboembolic events, the risks of adverse events exist and could outweigh benefits, so that overall mortality is unchanged or even increased. Extending dual antiplatelet therapy over 12 months might be considered but balance of risk and benefits should be tailored for individual patient.